Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative

Rowan T. Chlebowski, Joanne E. Mortimer, Carolyn J. Crandall, Kathy Pan, Jo Ann E. Manson, Rebecca Nelson, Karen Johnson, Mara Z. Vitolin, Dorothy Lane, Jean Wactawski-Wende, Karen Kwan, Marcia L. Stefanick

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Vasomotor symptoms (VMS) including hot flashes and night sweats are common during the menopausal transition and may persist. Although VMS pathophysiology is complex, estrogen's efficiency as VMS therapy suggests hormonal environment change may influence this process. As studies of VMS and breast cancer are inconsistent, we examined associations between persistent VMS and breast cancer incidence and mortality. METHODS: The analytic sample included 25,499 postmenopausal women aged 50 to 79 in the Women's Health Initiative (WHI) without current/former menopausal hormone therapy use with information on VMS status (never vs persistent). Breast cancers were verified by medical record review. Cause of death attribution was enhanced by serial National Death Index queries. Associations between VMS status and breast cancer incidence and mortality was determined using time dependent Cox regression analyses adjusted for breast cancer risk factors. RESULTS: Through 17.9 years (median) follow-up, 1,399 incident breast cancers were seen. Women with persistent VMS (VMS median duration 10+ years) (n = 9,715), compared to women with never VMS (n = 15,784), had a higher breast cancer incidence (hazard ratio [HR] 1.13 95% confidence interval [CI] 1.02-1.27). While breast cancer-specific mortality was higher in women with persistent VMS (HR 1.33 95% CI 0.88-2.02), the difference was not statistically significant. Persistent VMS status had no influence on breast cancer overall survival (HR 1.02 95% CI 0.81-1.29). CONCLUSION: Women with persistent VMS are more likely to be diagnosed with breast cancer than women who never experienced VMS, but not more likely to die from breast cancer.

Original languageEnglish (US)
Pages (from-to)578-587
Number of pages10
JournalMenopause (New York, N.Y.)
Volume26
Issue number6
DOIs
StatePublished - Dec 28 2018

Fingerprint

Women's Health
Breast Neoplasms
Confidence Intervals
Mortality
Incidence
Hot Flashes
Sweat
Medical Records
Cause of Death
Estrogens
Regression Analysis
Hormones

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Chlebowski, R. T., Mortimer, J. E., Crandall, C. J., Pan, K., Manson, J. A. E., Nelson, R., ... Stefanick, M. L. (2018). Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative. Menopause (New York, N.Y.), 26(6), 578-587. https://doi.org/10.1097/GME.0000000000001283

Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative. / Chlebowski, Rowan T.; Mortimer, Joanne E.; Crandall, Carolyn J.; Pan, Kathy; Manson, Jo Ann E.; Nelson, Rebecca; Johnson, Karen; Vitolin, Mara Z.; Lane, Dorothy; Wactawski-Wende, Jean; Kwan, Karen; Stefanick, Marcia L.

In: Menopause (New York, N.Y.), Vol. 26, No. 6, 28.12.2018, p. 578-587.

Research output: Contribution to journalArticle

Chlebowski, RT, Mortimer, JE, Crandall, CJ, Pan, K, Manson, JAE, Nelson, R, Johnson, K, Vitolin, MZ, Lane, D, Wactawski-Wende, J, Kwan, K & Stefanick, ML 2018, 'Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative', Menopause (New York, N.Y.), vol. 26, no. 6, pp. 578-587. https://doi.org/10.1097/GME.0000000000001283
Chlebowski RT, Mortimer JE, Crandall CJ, Pan K, Manson JAE, Nelson R et al. Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative. Menopause (New York, N.Y.). 2018 Dec 28;26(6):578-587. https://doi.org/10.1097/GME.0000000000001283
Chlebowski, Rowan T. ; Mortimer, Joanne E. ; Crandall, Carolyn J. ; Pan, Kathy ; Manson, Jo Ann E. ; Nelson, Rebecca ; Johnson, Karen ; Vitolin, Mara Z. ; Lane, Dorothy ; Wactawski-Wende, Jean ; Kwan, Karen ; Stefanick, Marcia L. / Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative. In: Menopause (New York, N.Y.). 2018 ; Vol. 26, No. 6. pp. 578-587.
@article{0b19fffc2aae4641b2896ead8be18c42,
title = "Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative",
abstract = "OBJECTIVE: Vasomotor symptoms (VMS) including hot flashes and night sweats are common during the menopausal transition and may persist. Although VMS pathophysiology is complex, estrogen's efficiency as VMS therapy suggests hormonal environment change may influence this process. As studies of VMS and breast cancer are inconsistent, we examined associations between persistent VMS and breast cancer incidence and mortality. METHODS: The analytic sample included 25,499 postmenopausal women aged 50 to 79 in the Women's Health Initiative (WHI) without current/former menopausal hormone therapy use with information on VMS status (never vs persistent). Breast cancers were verified by medical record review. Cause of death attribution was enhanced by serial National Death Index queries. Associations between VMS status and breast cancer incidence and mortality was determined using time dependent Cox regression analyses adjusted for breast cancer risk factors. RESULTS: Through 17.9 years (median) follow-up, 1,399 incident breast cancers were seen. Women with persistent VMS (VMS median duration 10+ years) (n = 9,715), compared to women with never VMS (n = 15,784), had a higher breast cancer incidence (hazard ratio [HR] 1.13 95{\%} confidence interval [CI] 1.02-1.27). While breast cancer-specific mortality was higher in women with persistent VMS (HR 1.33 95{\%} CI 0.88-2.02), the difference was not statistically significant. Persistent VMS status had no influence on breast cancer overall survival (HR 1.02 95{\%} CI 0.81-1.29). CONCLUSION: Women with persistent VMS are more likely to be diagnosed with breast cancer than women who never experienced VMS, but not more likely to die from breast cancer.",
author = "Chlebowski, {Rowan T.} and Mortimer, {Joanne E.} and Crandall, {Carolyn J.} and Kathy Pan and Manson, {Jo Ann E.} and Rebecca Nelson and Karen Johnson and Vitolin, {Mara Z.} and Dorothy Lane and Jean Wactawski-Wende and Karen Kwan and Stefanick, {Marcia L.}",
year = "2018",
month = "12",
day = "28",
doi = "10.1097/GME.0000000000001283",
language = "English (US)",
volume = "26",
pages = "578--587",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative

AU - Chlebowski, Rowan T.

AU - Mortimer, Joanne E.

AU - Crandall, Carolyn J.

AU - Pan, Kathy

AU - Manson, Jo Ann E.

AU - Nelson, Rebecca

AU - Johnson, Karen

AU - Vitolin, Mara Z.

AU - Lane, Dorothy

AU - Wactawski-Wende, Jean

AU - Kwan, Karen

AU - Stefanick, Marcia L.

PY - 2018/12/28

Y1 - 2018/12/28

N2 - OBJECTIVE: Vasomotor symptoms (VMS) including hot flashes and night sweats are common during the menopausal transition and may persist. Although VMS pathophysiology is complex, estrogen's efficiency as VMS therapy suggests hormonal environment change may influence this process. As studies of VMS and breast cancer are inconsistent, we examined associations between persistent VMS and breast cancer incidence and mortality. METHODS: The analytic sample included 25,499 postmenopausal women aged 50 to 79 in the Women's Health Initiative (WHI) without current/former menopausal hormone therapy use with information on VMS status (never vs persistent). Breast cancers were verified by medical record review. Cause of death attribution was enhanced by serial National Death Index queries. Associations between VMS status and breast cancer incidence and mortality was determined using time dependent Cox regression analyses adjusted for breast cancer risk factors. RESULTS: Through 17.9 years (median) follow-up, 1,399 incident breast cancers were seen. Women with persistent VMS (VMS median duration 10+ years) (n = 9,715), compared to women with never VMS (n = 15,784), had a higher breast cancer incidence (hazard ratio [HR] 1.13 95% confidence interval [CI] 1.02-1.27). While breast cancer-specific mortality was higher in women with persistent VMS (HR 1.33 95% CI 0.88-2.02), the difference was not statistically significant. Persistent VMS status had no influence on breast cancer overall survival (HR 1.02 95% CI 0.81-1.29). CONCLUSION: Women with persistent VMS are more likely to be diagnosed with breast cancer than women who never experienced VMS, but not more likely to die from breast cancer.

AB - OBJECTIVE: Vasomotor symptoms (VMS) including hot flashes and night sweats are common during the menopausal transition and may persist. Although VMS pathophysiology is complex, estrogen's efficiency as VMS therapy suggests hormonal environment change may influence this process. As studies of VMS and breast cancer are inconsistent, we examined associations between persistent VMS and breast cancer incidence and mortality. METHODS: The analytic sample included 25,499 postmenopausal women aged 50 to 79 in the Women's Health Initiative (WHI) without current/former menopausal hormone therapy use with information on VMS status (never vs persistent). Breast cancers were verified by medical record review. Cause of death attribution was enhanced by serial National Death Index queries. Associations between VMS status and breast cancer incidence and mortality was determined using time dependent Cox regression analyses adjusted for breast cancer risk factors. RESULTS: Through 17.9 years (median) follow-up, 1,399 incident breast cancers were seen. Women with persistent VMS (VMS median duration 10+ years) (n = 9,715), compared to women with never VMS (n = 15,784), had a higher breast cancer incidence (hazard ratio [HR] 1.13 95% confidence interval [CI] 1.02-1.27). While breast cancer-specific mortality was higher in women with persistent VMS (HR 1.33 95% CI 0.88-2.02), the difference was not statistically significant. Persistent VMS status had no influence on breast cancer overall survival (HR 1.02 95% CI 0.81-1.29). CONCLUSION: Women with persistent VMS are more likely to be diagnosed with breast cancer than women who never experienced VMS, but not more likely to die from breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85066922088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066922088&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000001283

DO - 10.1097/GME.0000000000001283

M3 - Article

VL - 26

SP - 578

EP - 587

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 6

ER -